The World Health Organization (WHO) has offered an urgent opportunity to develop a new vaccine for coronary heart disease, called Covovox, for the benefit of poor countries in particular.
The world’s largest vaccine manufacturer, Serum Institute in India, will produce the vaccine under the auspices of US company Novavax.
The current situation in the world, where the incidence of coronary heart disease is on the rise in many of the world’s richest countries, has led to the emergence of a new form of the disease, Omicron. no one will be saved if not everyone is saved.
Even before that, the World Health Organization (WHO) has been emphasizing the need to provide adequate immunizations for people in poor countries to run and survive together.
But WHO is concerned that rich countries, instead of ensuring adequate vaccination in poor countries, are accumulating more than they need for the future.
As a result of the current situation, this new Covovax vaccine will be produced, which will be distributed under the Covax International vaccine program for the benefit of these low-income countries only.
The World Health Organization says 41 of these countries account for less than 10 percent of the world’s population.
The new Covavax vaccine, in two rounds, is the first protein-rich vaccine to be approved by the World Health Organization.
The European Medicines Agency is still evaluating the exact product before the World Health Organization (WHO) examines it and then discusses its use.
Leave a Reply